• Je něco špatně v tomto záznamu ?

iGlarLixi (insulin glargine 100 U/ml plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real-world data

C. Guja, JT. Kis, M. Haluzík, M. Bonnemaire, G. Bigot, M. Tournay, N. Freemantle, J. Seufert

. 2023 ; 25 (6) : 1723-1730. [pub] 20230321

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23011291

AIM: To evaluate the effectiveness and safety in routine clinical practice of insulin glargine/lixisenatide (iGlarLixi) in people with type 2 diabetes (T2D) according to age. METHODS: Patient-level data were pooled from 1316 adults with T2D inadequately controlled on oral antidiabetic drugs with or without basal insulin who initiated iGlarLixi for 24 weeks. Participants were classified into age subgroups of younger than 65 years (N = 806) and 65 years or older (N = 510). RESULTS: Compared with participants aged younger than 65 years, those aged 65 years or older had a numerically lower mean body mass index (31.6 vs. 32.6 kg/m2 ), a longer median diabetes duration (11.0 vs. 8.0 years), were more likely to receive prior basal insulin (48.4% vs. 43.5%) and had a lower mean HbA1c (8.93% [74.10 mmol/mol] vs. 9.22% [77.28 mmol/mol]). Similar and clinically relevant reductions in HbA1c and fasting plasma glucose from baseline to week 24 of iGlarLixi therapy were observed regardless of age. At 24 weeks, least-squares adjusted mean (95% confidence interval [CI]) change in HbA1c from baseline was -1.55% (-1.65% to -1.44%) in those aged 65 years or older and -1.42% (-1.50% to -1.33%) in those aged younger than 65 years (95% CI: -0.26% to 0.00%; P = .058 between subgroups). Low incidences of gastrointestinal adverse events and hypoglycaemic episodes were reported in both age subgroups. iGlarLixi decreased mean body weight from baseline to week 24 in both subgroups (-1.6 kg in those aged ≥ 65 years and -2.0 kg in those aged < 65 years). CONCLUSIONS: iGlarLixi is effective and well tolerated in both younger and older people with uncontrolled T2D.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011291
003      
CZ-PrNML
005      
20230801132934.0
007      
ta
008      
230718s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/dom.15027 $2 doi
035    __
$a (PubMed)36810874
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Guja, Cristian $u Department of Diabetes, Nutrition and Metabolic Disease, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania $1 https://orcid.org/0000000287030522
245    10
$a iGlarLixi (insulin glargine 100 U/ml plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real-world data / $c C. Guja, JT. Kis, M. Haluzík, M. Bonnemaire, G. Bigot, M. Tournay, N. Freemantle, J. Seufert
520    9_
$a AIM: To evaluate the effectiveness and safety in routine clinical practice of insulin glargine/lixisenatide (iGlarLixi) in people with type 2 diabetes (T2D) according to age. METHODS: Patient-level data were pooled from 1316 adults with T2D inadequately controlled on oral antidiabetic drugs with or without basal insulin who initiated iGlarLixi for 24 weeks. Participants were classified into age subgroups of younger than 65 years (N = 806) and 65 years or older (N = 510). RESULTS: Compared with participants aged younger than 65 years, those aged 65 years or older had a numerically lower mean body mass index (31.6 vs. 32.6 kg/m2 ), a longer median diabetes duration (11.0 vs. 8.0 years), were more likely to receive prior basal insulin (48.4% vs. 43.5%) and had a lower mean HbA1c (8.93% [74.10 mmol/mol] vs. 9.22% [77.28 mmol/mol]). Similar and clinically relevant reductions in HbA1c and fasting plasma glucose from baseline to week 24 of iGlarLixi therapy were observed regardless of age. At 24 weeks, least-squares adjusted mean (95% confidence interval [CI]) change in HbA1c from baseline was -1.55% (-1.65% to -1.44%) in those aged 65 years or older and -1.42% (-1.50% to -1.33%) in those aged younger than 65 years (95% CI: -0.26% to 0.00%; P = .058 between subgroups). Low incidences of gastrointestinal adverse events and hypoglycaemic episodes were reported in both age subgroups. iGlarLixi decreased mean body weight from baseline to week 24 in both subgroups (-1.6 kg in those aged ≥ 65 years and -2.0 kg in those aged < 65 years). CONCLUSIONS: iGlarLixi is effective and well tolerated in both younger and older people with uncontrolled T2D.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    _2
$a senioři $7 D000368
650    12
$a diabetes mellitus 2. typu $x komplikace $x farmakoterapie $7 D003924
650    _2
$a inzulin glargin $x škodlivé účinky $7 D000069036
650    _2
$a glykovaný hemoglobin $7 D006442
650    _2
$a prospektivní studie $7 D011446
650    _2
$a krevní glukóza $7 D001786
650    _2
$a fixní kombinace léků $7 D004338
650    _2
$a hypoglykemika $x škodlivé účinky $7 D007004
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kis, János Tibor $u Department of Internal Medicine Centrum, Szent János Hospital, Budapest, Hungary
700    1_
$a Haluzík, Martin $u Institute for Clinical and Experimental Medicine and Charles University, Prague, Czech Republic
700    1_
$a Bonnemaire, Mireille $u General Medicines, Sanofi, Paris, France
700    1_
$a Bigot, Gregory $u IVIDATA, Paris, France
700    1_
$a Tournay, Mathilde $u International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium
700    1_
$a Freemantle, Nick $u Institute of Clinical Trials and Methodology, University College London, London, UK $1 https://orcid.org/0000000158075740
700    1_
$a Seufert, Jochen $u Division of Endocrinology and Diabetology, Department of Internal Medicine II, Medical Centre - Faculty of Medicine, University of Freiburg, Freiburg, Germany $1 https://orcid.org/0000000156547310
773    0_
$w MED00005425 $t Diabetes, obesity & metabolism $x 1463-1326 $g Roč. 25, č. 6 (2023), s. 1723-1730
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36810874 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132931 $b ABA008
999    __
$a ok $b bmc $g 1963598 $s 1197556
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 25 $c 6 $d 1723-1730 $e 20230321 $i 1463-1326 $m Diabetes, obesity and metabolism $n Diabetes Obes Metab $x MED00005425
LZP    __
$a Pubmed-20230718
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace